An act to amend Sections 49414 and 49423 of the Education Code, relating to pupil health, and declaring the urgency thereof, to take effect immediately.
AB 228, the Zackys Food Allergy Safety Treatment (FAST) Act, updates California Education Code provisions governing school access to emergency epinephrine for anaphylaxis response. The bill replaces references to “epinephrine auto-injectors” and “auto-injectable epinephrine” with the broader term “epinephrine delivery systems,” and requires school districts, county offices of education, and charter schools to provide at least one FDA-approved epinephrine delivery system for emergency use. It also preserves and updates related rules for storage, staff notice, volunteer training, restocking, and emergency administration at school sites and school activities.
The bill also amends the pupil self-administration statute so that students who are authorized to carry and use prescribed epinephrine may do so using a prescription auto-injectable epinephrine delivery system, subject to the same physician and parent/guardian written statements already required under existing law. It keeps the existing framework for school assistance with medication, annual documentation, and disciplinary consequences for misuse. AB 228 is drafted as an urgency measure, meaning it would take effect immediately upon enactment.
In practical terms, the bill would expand and modernize state requirements for school-based anaphylaxis preparedness by aligning statutory language with FDA-approved epinephrine delivery systems rather than only traditional auto-injectors. It would continue to impose duties on local educational agencies to stock, train, and maintain emergency epinephrine supplies and to provide defense and indemnification for volunteers who administer them. Because these are new or expanded duties on local agencies, the bill states that it creates a state-mandated local program and provides for reimbursement if the Commission on State Mandates so determines.
The overall sentiment reflected in the available voting history is favorable. The bill received an 8-0 do-pass vote in committee, indicating unanimous support among those voting at that stage. There are no committee transcript excerpts showing opposition or extended debate, and the bill’s urgency framing suggests proponents view the change as a timely public health and school safety update.
No specific points of contention are documented in the provided materials, but the main policy issue inherent in the bill is the shift from the older auto-injector terminology to a broader category of epinephrine delivery systems, along with the associated implementation burden on schools. Any concerns would likely center on cost, training, procurement, and compliance for local educational agencies, which is why the bill expressly addresses state-mandated reimbursement.
AB 228 would amend Education Code Sections 49414 and 49423 to update school epinephrine requirements statewide. It would require public schools, county offices of education, and charter schools to stock at least one FDA-approved epinephrine delivery system, maintain training and notice requirements, and continue allowing trained personnel to administer epinephrine in emergencies. It also updates student self-administration provisions to reflect epinephrine delivery systems and preserves liability protections, restocking rules, and emergency follow-up obligations. The bill would create a state-mandated local program to the extent it imposes new duties on local educational agencies, with reimbursement available if mandated costs are confirmed by the Commission on State Mandates.
The available record suggests strong support and little visible opposition. The bill advanced with an 8-0 committee vote, and there are no transcript excerpts indicating controversy or dissent. Its urgency clause and public-health framing indicate that supporters view the measure as a needed immediate update to school allergy response rules.
No explicit contention appears in the provided committee materials, but the likely areas of concern are operational rather than ideological: whether schools can quickly procure FDA-approved epinephrine delivery systems, train volunteers, and absorb any added administrative costs. The bill anticipates that issue by labeling the measure a state-mandated local program and providing for reimbursement if required. Another possible point of discussion is the terminology change from auto-injectors to broader delivery systems, which may raise implementation questions for schools and vendors.